Haemophilia is a rare genetic disorder characterized by the inability of blood to clot properly, leading to prolonged bleeding and bruising. It primarily affects males, as it is linked to the X chromosome. The prevalence of haemophilia varies depending on the type. Haemophilia A, the most common type, occurs in approximately 1 in every 5,000-10,000 male births. Haemophilia B is less common, affecting about 1 in every 20,000-34,000 male births. While haemophilia is considered rare, it is a significant health concern for those affected and their families.
Haemophilia is a rare genetic disorder that affects the blood's ability to clot properly. It is primarily an inherited condition, with two main types: Haemophilia A, caused by a deficiency of clotting factor VIII, and Haemophilia B, caused by a deficiency of clotting factor IX. The prevalence of Haemophilia varies depending on the type and geographical region.
Haemophilia A is the more common type, affecting approximately 1 in every 5,000 to 10,000 males worldwide. It is estimated that around 400,000 individuals are living with Haemophilia A globally. The condition can also occur in females, although it is much rarer.
Haemophilia B is less common, with an estimated prevalence of 1 in every 25,000 to 30,000 males worldwide. This means that there are around 20,000 individuals living with Haemophilia B globally.
It is important to note that these prevalence rates are approximate and can vary across different populations and regions. Additionally, advancements in medical care and treatment options have significantly improved the quality of life for individuals with Haemophilia, allowing them to manage the condition more effectively.